Seasonal malaria chemoprevention and the spread ofPlasmodium falciparumquintuple mutant parasites resistant to sulfadoxine-pyrimethamine: a modelling study

Author:

Masserey Thiery,Lee TamsinORCID,Kelly Sherrie LORCID,Hastings Ian MORCID,Penny Melissa AORCID

Abstract

SummaryBackgroundSeasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) prevents millions of clinical malaria cases in children under five in Africa’s Sahel region. However, parasites partially resistant to SP (with “quintuple” mutations) potentially threaten SMC protective effectiveness. We evaluated its spread and clinical consequences.MethodsAn individual-based malaria transmission model with explicit parasite dynamics and drug pharmacological models, was used to identify and quantify the influence of factors driving quintuple mutant spread and predict the time needed for the mutant to spread from 1% to 50% of inoculations for several SMC deployment strategies. We estimated the impact of this spread on SMC effectiveness against clinical malaria.FindingsHigher transmission intensity, SMC coverage, and expanded age range of chemoprevention promoted mutant spread. SMC implementation in a high transmission setting (40% parasite prevalence in children aged 2-10 years) with four monthly cycles to children aged three months to five years (with 95% initial coverage declining each cycle), the mutant requires 53·1 years (95% CI 50·5–56·0) to spread from 1% to 50% of inoculations. This time increased in lower transmission settings and reduced by half when SMC was extended to children under ten, or reduced by 10-13 years when an additional monthly cycle of SMC was deployed. For the same setting, the effective reduction in clinical cases in children receiving SMC was 79·0% (95% CI 77·8–80·8) and 60·4% (95% CI 58·6–62·3) during the months of SMC implementation when the mutant was absent or fixed in the population, respectively.InterpretationSMC with SP+AQ leads to a relatively slow spread of SP-resistant quintuple mutants and remains effective at preventing clinical malaria despite the mutant spread. SMC with SP+AQ should be considered in seasonal settings where this mutant is already prevalent.FundingSwiss National Science Foundation and Marie Curie Individual Fellowship.

Publisher

Cold Spring Harbor Laboratory

Reference74 articles.

1. World Health Organization. World malaria report 2020. Geneva; 2020. Available from: https://www.who.int/publications/i/item/9789240015791.

2. World Health Organization. Seasonal malaria chemoprevention with sulfadoxine– pyrimethamine plus amodiaquine in children: a field guide. Geneva; 2013. Available from: https://apps.who.int/iris/bitstream/handle/10665/85726/9789241504737_eng.pdf.

3. World Health Organization. WHO guideline for malaria. Geneva; 2022. Available from: https://www.who.int/publications/i/item/guidelines-for-malaria.

4. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study

5. Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3